Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions.
Bourdin A, Bjermer L, Brightling C, Brusselle GG, Chanez P, Chung KF, Custovic A, Diamant Z, Diver S, Djukanovic R, Hamerlijnck D, Horváth I, Johnston SL, Kanniess F, Papadopoulos N, Papi A, Russell RJ, Ryan D, Samitas K, Tonia T, Zervas E, Gaga M. Bourdin A, et al. Among authors: russell rj. Eur Respir J. 2019 Sep 28;54(3):1900900. doi: 10.1183/13993003.00900-2019. Print 2019 Sep. Eur Respir J. 2019. PMID: 31467120 Free article.
In vitro, in silico and in vivo study challenges the impact of bronchial thermoplasty on acute airway smooth muscle mass loss.
Chernyavsky IL, Russell RJ, Saunders RM, Morris GE, Berair R, Singapuri A, Chachi L, Mansur AH, Howarth PH, Dennison P, Chaudhuri R, Bicknell S, Rose FRAJ, Siddiqui S, Brook BS, Brightling CE. Chernyavsky IL, et al. Among authors: russell rj. Eur Respir J. 2018 May 24;51(5):1701680. doi: 10.1183/13993003.01680-2017. Print 2018 May. Eur Respir J. 2018. PMID: 29700102 Free PMC article.
Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Russell RJ, Chachi L, FitzGerald JM, Backer V, Olivenstein R, Titlestad IL, Ulrik CS, Harrison T, Singh D, Chaudhuri R, Leaker B, McGarvey L, Siddiqui S, Wang M, Braddock M, Nordenmark LH, Cohen D, Parikh H, Colice G, Brightling CE; MESOS study investigators. Russell RJ, et al. Lancet Respir Med. 2018 Jul;6(7):499-510. doi: 10.1016/S2213-2600(18)30201-7. Epub 2018 May 21. Lancet Respir Med. 2018. PMID: 29793857 Clinical Trial.
Cough and Eosinophilia.
Diver S, Russell RJ, Brightling CE. Diver S, et al. Among authors: russell rj. J Allergy Clin Immunol Pract. 2019 Jul-Aug;7(6):1740-1747. doi: 10.1016/j.jaip.2019.04.048. J Allergy Clin Immunol Pract. 2019. PMID: 31279462 Review.
Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial.
Yousuf AJ, Mohammed S, Carr L, Yavari Ramsheh M, Micieli C, Mistry V, Haldar K, Wright A, Novotny P, Parker S, Glover S, Finch J, Quann N, Brookes CL, Hobson R, Ibrahim W, Russell RJ, John C, Grimbaldeston MA, Choy DF, Cheung D, Steiner M, Greening NJ, Brightling CE. Yousuf AJ, et al. Among authors: russell rj. Lancet Respir Med. 2022 May;10(5):469-477. doi: 10.1016/S2213-2600(21)00556-7. Epub 2022 Mar 24. Lancet Respir Med. 2022. PMID: 35339234 Clinical Trial.
291 results